Théorêt Karina, Deng Jiahao, da Silva Sabrina Daniela, Guadagno Elena, Daniel Sam J
Department of Otolaryngology - Head and Neck Surgery, McGill University, Montreal, Quebec, Canada.
McGill Otolaryngology Sciences Laboratory, McGill University, Montreal, Quebec, Canada.
Laryngoscope. 2025 Oct;135(10):3472-3484. doi: 10.1002/lary.32229. Epub 2025 May 10.
The purpose of this study was to systematically review the differences in disease-specific quality of life (QoL) benefits experienced by bone-anchored hearing implant (BAHI) users between those diagnosed with unilateral sensorineural hearing loss (U-SNHL) and those with conductive/mixed hearing loss (CHL).
Eligible studies were searched for in Medline (Ovid), Embase (Ovid), CINAHL (Ebsco), Cochrane (Wiley), Global Health (Ovid), Web of Science (Clarivate Analytics), Africa Wide Information (Ebsco) and Global Index Medicus (WHO) from inception to October 23, 2022. Updated searches were performed on November 9, 2023, and July 11, 2024.
There were no restrictions on language. PRISMA standards were followed, and screening was conducted by two independent reviewers in Rayyan, with a third reviewer resolving conflicts. Risk of bias was assessed using RoBANS. Articles were included if patients were implanted with a BAHI and administered a validated, disease-specific QoL measure.
One thousand, three hundred twelve articles were identified after duplicate removal, with 56 articles meeting the inclusion criteria. Eight different disease-specific QoL measures were administered. In all, the APHAB's "Global" (p = 0.0002), EC (p < 0.00001), and BN (p = 0.02) scores, as well as the GBI's "Global" (p = 0.0001), "General" (p = 0.002), and "Physical" (p = 0.02) scores were significantly different between U-SNHL and CHL populations.
These results demonstrated disease-specific QoL differences between BAHI users with U-SNHL and CHL. Specifically, patients with CHL reported greater benefits in domains pertaining to communication ease, the clarity of sound, and their overall health and psychosocial status.
本研究旨在系统回顾骨锚式助听器（BAHI）使用者中，单侧感音神经性听力损失（U-SNHL）患者与传导性/混合性听力损失（CHL）患者在特定疾病生活质量（QoL）获益方面的差异。
从数据库建库至2022年10月23日，在Medline（Ovid）、Embase（Ovid）、CINAHL（Ebsco）、Cochrane（Wiley）、Global Health（Ovid）、Web of Science（Clarivate Analytics）、Africa Wide Information（Ebsco）和Global Index Medicus（WHO）中检索符合条件的研究。于2023年11月9日和2024年7月11日进行了更新检索。
对语言无限制。遵循PRISMA标准，由两名独立评审员在Rayyan进行筛选，第三名评审员解决冲突。使用RoBANS评估偏倚风险。若患者植入了BAHI并接受了经过验证的特定疾病QoL测量，则纳入相关文章。
去除重复文章后共识别出1312篇文章，其中56篇符合纳入标准。使用了8种不同的特定疾病QoL测量方法。总体而言，U-SNHL和CHL人群在APHAB的“总体”（p = 0.0002）、“EC”（p < 0.00001）和“BN”（p = 0.02）得分，以及GBI的“总体”（p = 0.0001）、“一般”（p = 0.002）和“身体”（p = 0.02）得分上存在显著差异。
这些结果表明，U-SNHL和CHL的BAHI使用者在特定疾病QoL方面存在差异。具体而言，CHL患者在沟通便利性、声音清晰度以及整体健康和心理社会状况等方面报告的获益更大。
